



WHO collaborative registration procedure to assure access to modern DR-TB medicines




Webinar of the Collaborating Network

December 2, 2020



All pharmaceutical products, including multisource products, should be used in a country **only after approval** by the national or regional authority. Regulatory authorities should require the documentation of a multisource pharmaceutical product to meet the following:


- GMP;
- QC specifications;
- **pharmaceutical product interchangeability**



WHA Resolutions: WHA 67.20 (2014); WHA 67.21 (2014); WHA63.12 (2010)


IDEAL SITUATION

Robust Registration Systems



Medicines Regulation Process Flow

Registration processes not optimized



Medicines Regulation Process Flow

WHO Prequalification

In vitro
Diagnostics 2010
HIV test kit evaluation
1988



WHO PQ Process

INPUTS

Expression of Interest



Dossier

WHO Guidelines



Assessors/
Inspectors

Testing

PROCESS

Assessment of Dossier



Inspections
(API, FPP,
CRO)

Assessment/
Inspection/Lab
Reports

OUTPUTS

List of
Prequalified
products

WHO Public
Reports

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fiftieth report

Annex 8

Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines

1. Definitions	264
2. Background information	265
3. Principles of collaboration	267
4. Steps in the collaboration for national registration of a pharmaceutical product or a vaccine	274
5. Collaboration mechanisms for post-prequalification and/or post-registration variations	279
6. Withdrawals, suspensions or delistings of prequalified pharmaceutical products or vaccines and national deregistrations	280
References	281
Appendix 1 National regulatory authority participation agreement and undertaking for national regulatory authority focal point(s)	282
Appendix 2 Consent of WHO prequalification holder for WHO to share information with the national regulatory authority confidentially under the Procedure	292
Appendix 3 Expression of interest to national regulatory authority (NRA) in the assessment and accelerated national registration, acceptance by NRA and notification of Procedure outcomes	295
Appendix 4 Report on post-registration actions in respect of a product registered under the Procedure	303

<http://apps.who.int/iris/bitstream/handle/10665/255338/9789241209960-eng.pdf?sequence=1>

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-second report

Annex 11

Collaborative procedure in the assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities

1. Background information	272
2. Glossary	273
3. Principles of collaborative procedure	275
4. Medicines	278
5. Collaboration mechanisms for management of post-registration variations	284

<http://apps.who.int/iris/bitstream/handle/10665/272452/9789241210195-eng.pdf?ua=1>




Concept of facilitated registrations (Reliance)

To support the national registrations, regulators can benefit from already organized scientific assessments and inspections, if

- Having access to regulatory expertise from trusted party (complete assessment and inspection reports)
- Having the same product
- Having same essential technical data
- National legislation and sovereignty are not affected
- Respect confidentiality of commercially sensitive information
- Manage properly regulatory follow-up

How does the collaborative procedures works?



Win-win outcomes for all stakeholders

NRA

- Having data well organized in line with PQ requirements
- Availability of unredacted WHO assessment and inspection outcomes to support national decisions and save internal capacities
- Having assurance about registration of 'the same' product as is prequalified (in this case, US FDA approved/tentatively approved products)

Manufacturers

- Harmonized data for PQ and national registration
- Facilitated interaction with NRAs in assessment, inspections
- Accelerated and more predictable registration
- Easier post-registration maintenance

WHO

- Prequalified products are faster available to patients
- Feed-back on WHO prequalification outcomes

Procurers

- Time,
- Assurance,
- Availability


NTP

WHO PQ CRP



Median = 85 days

manufacturer



609 registrations



34 plus countries

As at 25 Nov 2020

Participating NRAs

- **Armenia**
- **Azerbaijan**
- **Belarus**
- Bhutan
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Caribbean Community (CARICOM)
- Comores
- Côte d'Ivoire
- Democratic Republic of the Congo
- Eritrea
- Ethiopia
- **Georgia**
- Ghana
- **Kazakhstan**
- Kenya
- **Kyrgyzstan**
- Lao People's Democratic Republic
- Madagascar
- Malawi
- Malaysia
- Mali
- Mozambique
- Namibia
- Nigeria
- Pakistan
- Philippines
- Rwanda
- Senegal
- Sierra Leone
- South Africa
- Sri Lanka
- Sudan
- Tanzania
- Thailand
- Togo
- Uganda
- **Ukraine**
- **Uzbekistan**
- Zambia
- Zanzibar
- Zimbabwe

* CARICOM


Member States: Antigua and Barbuda, Bahamas, Belize, Dominica, Grenada, Haiti, Jamaica, Montserrat, Saint Lucia, St. Kitts and Nevis, St Vincent and the Grenadines, Suriname and Trinidad and Tobago

Associate Member States: Anguilla, Bermuda, British Virgin Islands, Cayman Islands and Turks and Caicos Islands


As at 1 Dec 2020

WHO European Region

Countries



Therapeutic area



Total registrations: 51 (As at 25 Nov 2020)

Thank you

WHO Regional Office for Europe

UN City
Marmorvej 51
Copenhagen Ø
Denmark



WHO_Europe



facebook.com/WHOEurope



instagram.com/whoeurope



youtube.com/user/whoeuro



World Health
Organization

REGIONAL OFFICE FOR
Europe



Organisation
mondiale de la Santé

BUREAU RÉGIONAL DE L'
Europe



Weltgesundheitsorganisation

REGIONALBÜRO FÜR
Europa



Всемирная организация
здравоохранения

Европейское региональное бюро